TRBJ2-3: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: TRBJ2-3

NCBI ID: G28626

TRBJ2-3

Other Name(s): TCRBJ2S3 | T cell receptor beta joining 2-3 | TRBJ23

TRBJ2-3: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

TRBJ2-3 (Tumor-associated regulatory RNA 2-3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and expression patterns have made it an attractive target for researchers to study, and its functions continue to be a subject of debate in the scientific community.

TRBJ2-3 is a small RNA molecule that is expressed in various tissues and cells of the body, including the brain, heart, liver, and pancreas. Its primary function is to regulate gene expression by binding to specific DNA sequences, a process known as RNA-protein interactions. This interaction between TRBJ2-3 and DNA allows it to regulate the activity of gene promoters, ultimately leading to the expression or regulation of target genes.

One of the unique features of TRBJ2-3 is its structure. It is a small RNA molecule with only 194 amino acid residues, and its primary function is to interact with DNA. Its 3' end has a unique structure that contains a conserved G -Crich sequence, which is known as a G-box. This G-box is a common structural feature in RNA molecules that plays a role in their stability and stability interactions.

TRBJ2-3 has been shown to play a role in various diseases, including cancer. In cancer, TRBJ2-3 is expressed at higher levels than in normal tissues and has been associated with the development and progression of cancer. For example, studies have shown that TRBJ2-3 is overexpressed in various types of cancer, including breast, lung, and colorectal cancer.

In addition to its potential as a drug target, TRBJ2-3 has also been identified as a potential biomarker. Its expression patterns have been shown to be altered in various diseases, including cancer. For example, studies have shown that TRBJ2-3 is downregulated in various types of cancer, including breast, lung, and colorectal cancer, and its expression is associated with cancer progression.

TRBJ2-3 has also been shown to play a role in the regulation of cellular processes, including cell cycle progression and apoptosis. For example, studies have shown that TRBJ2-3 is involved in the regulation of the G1/S transition, which is a critical step in the cell cycle and is associated with the transition from quiescence to active cell division.

In conclusion, TRBJ2-3 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and expression patterns have made it an attractive target for researchers to study, and its functions continue to be a subject of debate in the scientific community. Further research is needed to fully understand the role of TRBJ2-3 in disease and to develop effective treatments.

Protein Name: T Cell Receptor Beta Joining 2-3

Functions: J region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBJ2-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBJ2-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets